5. Metabolite Identification Using Mass Spectrometry in Drug Development

  1. Walter A. Korfmacher
  1. Natalia Penner1,
  2. Joanna Zgoda-Pols2 and
  3. Chandra Prakash1

Published Online: 17 JAN 2013

DOI: 10.1002/9781118516157.ch5

Mass Spectrometry for Drug Discovery and Drug Development

Mass Spectrometry for Drug Discovery and Drug Development

How to Cite

Penner, N., Zgoda-Pols, J. and Prakash, C. (2013) Metabolite Identification Using Mass Spectrometry in Drug Development, in Mass Spectrometry for Drug Discovery and Drug Development (ed W. A. Korfmacher), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118516157.ch5

Editor Information

  1. Genzyme, a SANOFI Company, Waltham, MA, USA

Author Information

  1. 1

    Cambridge Center, Biogen Idec, Cambridge, MA, USA

  2. 2

    Merck Research Laboratories, Rahway, NJ, USA

Publication History

  1. Published Online: 17 JAN 2013
  2. Published Print: 22 JAN 2013

Book Series:

  1. Wiley Series on Mass Spectrometry

Book Series Editors:

  1. Dominic M. Desiderio4 and
  2. Nico M. M. Nibbering5

Series Editor Information

  1. 4

    Departments of Neurology and Biochemistry, University of Tennessee Health Science Center, USA

  2. 5

    Vrije Universiteit Amsterdam, The Netherlands

ISBN Information

Print ISBN: 9780470942383

Online ISBN: 9781118516157

SEARCH

Keywords:

  • metabolite identification, MS in drug development;
  • discovery metabolite identification;
  • metabolite profiling studies;
  • FIH/GLP-toxicology, and full scan HPLC-MS;
  • current HPLC-MS, in silico/HPLC-MS software

Summary

This chapter contains sections titled:

  • Introduction

  • Metabolite Profiling in Studies without Radiolabeled Test Article

  • Metabolite Profiling in Studies with Radiolabeled Test Article

  • Summary and Future Trends

  • References